Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 3:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 33,013 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo controlled Clear all

Conditions: Pain
Interventions: Botulinum Toxin A, Placebo - Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus
Interventions: HM11260C, Placebo; Drug
Lead sponsor: Hanmi Pharmaceutical Company Limited; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Ohio City, Ohio

Conditions: HIV Infections
Interventions: VH4004280, VH4011499, VH4004280 Matching Placebo, VH4011499 Matching Placebo, Antiretroviral therapy; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 3
States / cities: Bakersfield, California • DeLand, Florida • Newark, New Jersey

Conditions: Opioid-induced Constipation
Interventions: Methylnaltrexone bromide, Placebo; Drug
Lead sponsor: Bausch Health Americas, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Tarrytown, New York

Conditions: Cardiovascular Disease
Interventions: Purple Grape Juice; Dietary Supplement
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Murray, Utah

Conditions: Pain
Interventions: Buprenorphine, Placebo; Drug
Lead sponsor: INSYS Therapeutics Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 4
States / cities: Phoenix, Arizona • Anaheim, California • Pasadena, Maryland + 1 more

Conditions: Interstitial Cystitis
Interventions: LiRIS 400 mg, LiRIS Placebo; Drug · Other
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 15
States / cities: Glendora, California • Daytona Beach, Florida • Kansas City, Kansas + 12 more

Conditions: Alcohol Dependence
Interventions: LY686017, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 21 Years to 65 Years
Enrollment: 190 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 21
States / cities: Oceanside, California • San Diego, California • Deerfield Beach, Florida + 18 more

Conditions: Urinary Bladder Overactive, Urinary Bladder Diseases\Urologic Diseases, Overactive Bladder, Urgency Incontinence
Interventions: Solifenacin succinate, Mirabegron, Placebo to match solifenacin succinate, Placebo to match mirabegron; Drug
Lead sponsor: Astellas Pharma Europe B.V.; Industry
Eligibility: 18 Years and older
Enrollment: 3,527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 121
States / cities: Mobile, Alabama • Chandler, Arizona • Phoenix, Arizona + 96 more

Conditions: Clinical Pharmacology, Healthy Volunteer Study
Interventions: Placebo, Pomalidomide, Moxifloxacin; Drug
Lead sponsor: Celgene; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Arnold-Chiari Malformation, Posterior Fossa Tumors
Interventions: IV acetaminophen, normal saline; Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 2 Years to 12 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Persistent Pulmonary Hypertension, Respiratory Failure
Interventions: Intravenous Sildenafil, Placebo; Drug · Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: Up to 72 Hours
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 7
States / cities: Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more

Conditions: COVID-19
Interventions: Brilacidin, Placebo, Standard of Care (SoC); Drug
Lead sponsor: Innovation Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 2
States / cities: Winfield, Illinois • Toledo, Ohio

Conditions: Migraine
Interventions: LY3451838, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Phoenix, Arizona • Stamford, Connecticut • Ocala, Florida + 6 more

Conditions: Acute Pain, Postoperative Pain Control
Interventions: Experimental: LTG-001 High Dose, Experimental: LTG-001 Low Dose, Active Comparator: HB/APAP, Placebo Comparator; Drug
Lead sponsor: Latigo Biotherapeutics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Phoenix, Arizona • Atlanta, Georgia • Houston, Texas + 2 more

Conditions: Dry Eye
Interventions: OmegaD, Placebo; Drug
Lead sponsor: OmegaD LLC; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 11
States / cities: Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more

Conditions: Hypertension
Interventions: aliskiren; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 641 participants
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Mitochondrial Encephalopathy, Lactic Acidosis and Stroke-Like Episodes (MELAS Syndrome)
Interventions: zagociguat 15mg, zagociguat 30mg, Placebo; Drug
Lead sponsor: Tisento Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 10
States / cities: La Jolla, California • Aurora, Colorado • Atlanta, Georgia + 5 more

Conditions: HIV Infections
Interventions: Inosine pranobex; Drug
Lead sponsor: Newport Pharmaceuticals International; Industry
Eligibility: 18 Years and older · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Laguna Hills, California

Conditions: Hysterectomy, Post Operative Analgesia
Interventions: Bupivacain, Saline (NaCl 0,9 %) (placebo); Drug · Other
Lead sponsor: MediSys Health Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Flushing, New York

Conditions: Atopic Dermatitis
Interventions: EDP1815, Placebo; Drug
Lead sponsor: Evelo Biosciences, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 421 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 27
States / cities: Birmingham, Alabama • Fountain Valley, California • Fremont, California + 22 more

Conditions: Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions: Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more

Conditions: Acquired Bleeding Disorder, Cardiac Surgery Requiring Cardiopulmonary Bypass
Interventions: catridecacog, placebo; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 35 Years to 70 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 15
States / cities: Tucson, Arizona • San Francisco, California • Denver, Colorado + 10 more

Conditions: Ataxia Telangiectasia
Interventions: Baclofen, Placebo; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 12 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 2
States / cities: Baltimore, Maryland

Search by objective public record fields.

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Study of Subcutaneous Methylnaltrexone (MNTX) in the Treatment of Opioid-Induced Constipation During Rehabilitation After Orthopedic Procedures

The Purple Grape Juice Study

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Safety, Tolerability and Efficacy Study of LiRIS® 400 mg in Women With Interstitial Cystitis

A Study in the Treatment of Alcohol Dependence.

This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder

A Phase 1 QT Study in Healthy Male Subjects

Efficacy of Acetaminophen in Posterior Fossa Surgery

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

A Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

A Study of LY3451838 in Participants With Migraine

An Efficacy and Safety Study of LTG-001 Following Abdominoplasty

Study of the Safety and Efficacy of OmegaD Softgels in the Treatment of Dry Eye Disease

A Dose Ranging Study to Compare the Safety and Efficacy of Aliskiren in Patients With High Blood Pressure

A Phase 2b Study of Zagociguat in Patients With MELAS

A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers

Vaginal Cuff Anesthesia and Post-Operative Pain Medication Use

A Study Investigating the Effect of EDP1815 in the Treatment of Mild, Moderate and Severe Atopic Dermatitis

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

Safety of rFXIII in Patients Following First Time Myocardial Revascularization Requiring Cardiopulmonary Bypass

Baclofen Treatment of Ataxia Telangiectasia